PMID- 11966543
OWN - NLM
STAT- MEDLINE
DCOM- 20020715
LR  - 20190901
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 16 Suppl 2
DP  - 2002 Apr
TI  - Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer 
      disease.
PG  - 204-9
AB  - BACKGROUND: The NIH consensus conference in 1994 recommended that all patients 
      with peptic ulcers should be tested and treated for Helicobacter pylori. Recent 
      studies have shown that the eradication of H. pylori is associated with a 
      significant reduction in the relapse rate of peptic ulcers, but there are few 
      reports about long-term outcome. AIMS: To evaluate the relapse rate of peptic 
      ulcer in the long-term follow-up of patients after H. pylori eradication therapy. 
      PATIENTS AND METHODS: Patients infected with H. pylori (445; 88 duodenal ulcer, 
      357 gastric ulcer) were randomly divided into three groups. In group A, patients 
      received 'conventional treatment' including acid decreasing therapy with a 
      histamine H2-receptor antagonist or proton pump inhibitor (PPI). In group B, 
      patients received 'dual therapy' including one antibiotic plus acid-decreasing 
      therapy. In group C, patients received 'triple therapy' with PPI plus amoxicillin 
      and clarithromycin. Eradication of H. pylori infection was assessed by histology 
      of biopsy specimens from both the antrum and body corpus at 4 weeks, and 6 and 12 
      months after stopping therapy. Endoscopy was performed at intervals of 6 months 
      for 5 years. RESULTS: Intention-to-treat eradication rates for the duodenal ulcer 
      patients were 0% for group A, 46% for group B and 80% for group C; eradication 
      rates for the gastric ulcer patients were 0%, 33% and 83% respectively. No 
      recurrence was noted in the duodenal ulcer patients and only 4% of gastric ulcers 
      recurred after successful eradication during follow-up for 5 years. In contrast, 
      in patients with persistent H. pylori infection all DU and 92% of gastric ulcers 
      recurred. CONCLUSION: Eradication of H. pylori infection changes the natural 
      course of peptic ulcer.
FAU - Tomita, T
AU  - Tomita T
AD  - Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Hyogo, 
      Japan.
FAU - Fukuda, Y
AU  - Fukuda Y
FAU - Tamura, K
AU  - Tamura K
FAU - Tanaka, J
AU  - Tanaka J
FAU - Hida, N
AU  - Hida N
FAU - Kosaka, T
AU  - Kosaka T
FAU - Hori, K
AU  - Hori K
FAU - Sakagami, T
AU  - Sakagami T
FAU - Satomi, M
AU  - Satomi M
FAU - Shimoyama, T
AU  - Shimoyama T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Helicobacter Infections/*complications/*drug therapy
MH  - Helicobacter pylori/*isolation & purification
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Peptic Ulcer/*etiology/*prevention & control
MH  - Proton Pump Inhibitors
MH  - Secondary Prevention
MH  - Treatment Outcome
EDAT- 2002/04/23 10:00
MHDA- 2002/07/16 10:01
CRDT- 2002/04/23 10:00
PHST- 2002/04/23 10:00 [pubmed]
PHST- 2002/07/16 10:01 [medline]
PHST- 2002/04/23 10:00 [entrez]
AID - 152 [pii]
AID - 10.1046/j.1365-2036.16.s2.24.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:204-9. doi: 
      10.1046/j.1365-2036.16.s2.24.x.